COMMUNIQUÉS West-GlobeNewswire

Summit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before Expenses

14/09/2017 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Summit Therapeutics plc (" [...]

Terveystalo is planning an initial public offering and a listing on Nasdaq Helsinki Ltd

14/09/2017 - 07:48

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA [...]

Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study

14/09/2017 - 07:15

51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira ® * safety and efficacy profile[1] Sandoz proposed biosimilar adalimumab is currently under review by the [...]

ABLYNX ANNOUNCES WARRANT EXERCISE

14/09/2017 - 07:00

REGULATED INFORMATION GHENT, Belgium, 14 September 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that [...]

Bone Therapeutics SA : Reports strong interim results from ALLOB® Phase IIA spinal fusion study

14/09/2017 - 07:00

Regulated information Bone Therapeutics reports strong interim results from ALLOB ® Phase IIA spinal fusion study Significant clinical and radiological improvements compared to baseline Results pave the way for future [...]

Bone Therapeutics SA : Annonce des résultats intermédiaires robustes dans l'étude de phase IIA avec ALLOB® dans la fusion vertébrale

14/09/2017 - 07:00

Information réglementée Bone Therapeutics annonce des résultats intermédiaires robustes dans l'étude de phase IIA avec ALLOB ® dans la fusion vertébrale Améliorations cliniques et radiologiques significatives par [...]

New Five-Year Gender Subset Data from the Medtronic Engage Registry Presented in VIVA Late Breaking Trials

13/09/2017 - 19:49

Five-Year, Real-World Data Demonstrate EVAR Outcomes with Endurant® II Stent Graft System Are Comparable in Both Male and Female Patients DUBLIN and LAS VEGAS - September 13, 2017 - Medtronic plc (NYSE: MDT) today [...]

CROSSJECT : Mise en oeuvre d'un contrat de liquidité

13/09/2017 - 18:37

Mise en oeuvre d'un contrat de liquidité avec Kepler Dijon, le 13 septembre 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de médicaments combinés innovants [...]

CROSSJECT : Bilan de fin de contrat de liquidité

13/09/2017 - 18:32

Bilan de fin de contrat de liquidité conclu avec CM-CIC Market Solutions Dijon, le 13 septembre 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de médicaments [...]

CROSSJECT : Descriptif du programme de rachat d'actions

13/09/2017 - 18:28

Descriptif du programme de rachat d'actions 2017-2018 Dijon, le 13 septembre 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de médicaments combinés innovants [...]

CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social

13/09/2017 - 18:20

Information relative au nombre total de droits de vote et d'actions composant le capital social 13 septembre 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de [...]

Xultophy® reduces cardiovascular risk factors in people with type 2 diabetes

13/09/2017 - 16:32

Lisbon, Portugal, 13 September 2017 - In people with type 2 diabetes, Xultophy ® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease [...]

CrownBio's Integrated Oncology Platform Helps Advance Apogenix's Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer

13/09/2017 - 16:27

SANTA CLARA, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company [...]

Solon Eiendom ASA : Finansiell kalender

13/09/2017 - 16:19

(Oslo, Norge, 13 september 2017) Solon Eiendom ASA har gjort følgende endringer i finansiell kalender for 2017: 9 November 2017 Kvartalsrapport Q3 Presentasjonen er fremskyndet for å gi mest mulig tidsriktig informasjon [...]

Solon Eiendom ASA : Financial calender

13/09/2017 - 16:18

(Oslo, Norway, 13 September 2017) Solon Eiendom ASA has rescheduled its financial calendar 2017 as follows: 9 November 2017 Q3 2017 Interim Financial Report In order to present information more timely we have decided to [...]

ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer's Disease

13/09/2017 - 13:30

TORONTO and CAMBRIDGE, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced it has [...]

RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.

13/09/2017 - 13:00

Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and [...]

NuCana Announces Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373

13/09/2017 - 13:00

Received Best Poster Presentation Award at ESMO 2017 EDINBURGH, United Kingdom, Sept. 13, 2017 (GLOBE NEWSWIRE) -- NuCana plc announced the presentation of interim first-in-human data from a Phase 1 clinical study of [...]

Soliqua® 100/33 provided earlier blood sugar control than insulin glargine 100 units/mL

13/09/2017 - 12:17

Press release - No. 7/2017 Soliqua ® 100/33 provided earlier blood sugar control than insulin glargine 100 units/mL More adults reached HbA 1c target at 8 and 12 weeks versus those receiving insulin glargine 100 units/ [...]